Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study Program to Investigate the Effectiveness of Intravitreal Aflibercept in Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion in a Real World Setting

Next Previous
X
Search
Trial Profile

An Observational Study Program to Investigate the Effectiveness of Intravitreal Aflibercept in Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion in a Real World Setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms AURIGA
  • Sponsors Bayer

    • Most Recent Events

    • 17 Apr 2023 According to Regeneron Pharmaceuticals media release, data from this study will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
    • 21 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2021 Planned End Date changed from 30 Nov 2021 to 17 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top